National Institute of Allergy and Infectious Diseases (NIAID) sponsored Adaptive COVID-19 Treatment Trial reports speedier recovery from COVID-19

Preliminary results from trial (n=1063) showed those hospitalised with advanced COVID-19 and lung involvement on remdesivir recovered faster than patients on placebo (11 vs. 15 days), recovery defined as being well enough for hospital discharge/returning to normal activity level.